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Abstract: Upon liver injury, hepatic stellate cells (HSCs) transdifferentiate to migratory, proliferative
and extracellular matrix-producing myofibroblasts (e.g., activated HSCs; aHSCs) causing liver fibrosis.
HSC activation is associated with increased glycolysis and glutaminolysis. Here, we compared the
contribution of glycolysis, glutaminolysis and mitochondrial oxidative phosphorylation (OXPHOS)
in rat and human HSC activation. Basal levels of glycolysis (extracellular acidification rate ~3-fold
higher) and particularly mitochondrial respiration (oxygen consumption rate ~5-fold higher) were
significantly increased in rat aHSCs, when compared to quiescent rat HSC. This was accompanied
by extensive mitochondrial fusion in rat and human aHSCs, which occurred without increasing
mitochondrial DNA content and electron transport chain (ETC) components. Inhibition of glycolysis
(by 2-deoxy-D-glucose) and glutaminolysis (by CB-839) did not inhibit rat aHSC proliferation,
but did reduce Acta2 (encoding α-SMA) expression slightly. In contrast, inhibiting mitochondrial
OXPHOS (by rotenone) significantly suppressed rat aHSC proliferation, as well as Col1a1 and Acta2
expression. Other than that observed for rat aHSCs, human aHSC proliferation and expression
of fibrosis markers were significantly suppressed by inhibiting either glycolysis, glutaminolysis or
mitochondrial OXPHOS (by metformin). Activation of HSCs is marked by simultaneous induction of
glycolysis and mitochondrial metabolism, extending the possibilities to suppress hepatic fibrogenesis
by interfering with HSC metabolism.
Keywords: cell metabolism; liver fibrosis; mitochondria
1. Introduction
Liver fibrosis is characterized by the intrahepatic accumulation of connective tissue as a consequence
of chronic liver injury. This process occurs in most types of chronic liver diseases, including immune-,
viral-, alcoholic- and metabolic-mediated forms [1]. Liver fibrosis may progress to cirrhosis, where the
liver architecture is disrupted due to the accumulation of extracellular matrix (ECM) and may ultimately
lead to liver failure [1]. Moreover, patients with cirrhosis are at increased risk to develop hepatocellular
carcinoma. Liver transplantation is then the only available therapy left [2]. Fortunately, accumulating
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evidence reveals that liver fibrosis in early stages is largely reversible [2] and major efforts are being
made to develop new drug-based therapies to reverse liver fibrosis and/or prevent progression
to cirrhosis.
The main cell type involved in liver fibrosis is the hepatic stellate cell (HSC). HSCs are responsible
for producing most of the ECM proteins, like collagens and fibronectins that accumulate in the
chronically injured liver. HSCs in the healthy liver are considered “quiescent” (qHSCs), reside in the
space of Disse, store vitamin A in large cytoplasmic lipid droplets and express high levels of the lipogenic
transcription factor peroxisome proliferator-activated receptor gamma (PPAR-γ) [3]. The qHSCs contain
the largest reserves of vitamin A in the human body and are considered key regulators of systemic
distribution to vitamin A-requiring peripheral tissues [4]. Upon liver injury, however, qHSCs lose their
vitamin A and lipid stores, turn down PPAR-γ expression and transdifferentiate into myofibroblast-like
cells (e.g., activated HSCs (aHSCs)) that are highly proliferative, contractile, migratory and produce
excessive amounts of extracellular matrix proteins, including collagen I and III [5]. The aHSCs express
alpha-smooth muscle actin (α-SMA) and produce pro-inflammatory and pro-fibrogenic cytokines,
like TGF-β [3,6]. Hepatic stellate cell activation is central to the development of fibrosis and thus an
important process to target in the quest to treat liver fibrosis.
Furthermore, inhibiting these metabolic pathways has been shown to prevent the undergoing
activation in vitro [7,8]. It has been recently demonstrated that plastic-cultured aHSCs have enhanced
oxidative phosphorylation and glycolysis compared to less activated matrigel-cultured aHSCs [9].
However, functional analyses to quantify metabolic processes that differentiate freshly isolated
qHSCs versus culture-activated HSCs have not been reported yet. Here, we hypothesize that HSC
transdifferentiation is not only accompanied by a shift to glycolysis and glutaminolysis, but also an
induction of mitochondrial oxidative phosphorylation (OXPHOS) to meet the high energy demand
of aHSCs. Thus, the objectives of this study were to investigate the contribution of mitochondrial tic
metabolism in the activation process of HSCs and identify new mitochondrial targets for the treatment
of liver fibrosis.
2. Materials and Methods
2.1. Reagents
Fully activated rat and human HSCs (at least 7 days in culture) were treated for 3 days with
2.5 mmol/L 2-Deoxy-D-glucose (2DG, D8375, Sigma, Saint Luis, MO, USA) or 5 µmol/L GLS1 inhibitor
(CB-839, 5.33717, EMD Millipore, Burlington, NJ, USA) to inhibit glycolysis or glutaminolysis,
respectively. OXPHOS was inhibited by either 5 µmol/L rotenone (R8875, Sigma) or 2 mmol/L
metformin (317240, EMD Millipore).
2.2. Rat and Human HSC Isolation, Cell Culture and Treatments
Primary rat hepatic stellate cells were isolated by a two-step perfusion of the liver with pronase
(Merck, Amsterdam, The Netherlands) and collagenase-P (Roche, Almere, The Netherlands) and
further purified by Nycodenz (Axis-ShieldPOC, Oslo, Norway) gradient centrifugation, as described
before [10]. HSCs were cultured in Iscove’s modified Dulbecco’s medium (IMDM) with Glutamax
(Invitrogen, Breda, The Netherlands) supplemented with 20% heat-inactivated fetal calf serum (FCS,
Invitrogen), 1 mmol/L sodium pyruvate (Invitrogen), 1x MEM non-essential amino acids (Invitrogen),
50 µg/mL gentamicin (Invitrogen) and penicillin–streptomycin–fungizone (PSF) in a humidified
incubator at 37 ◦C with 5% CO2. Freshly isolated quiescent rat HSCs (r-qHSCs) were allowed to attach
to culture plates for 4 or 24 h and harvested (r-qHSCs), or cultured for 7 days to become fully activated
rHSCs (r-aHSCs). After 7 days, cells were trypsinized and seeded for experiments.
Primary human HSCs were isolated from macroscopically normal liver specimens obtained from
fresh tumor resections by an “all-in-one” liver cell purification procedure, as described previously [11].
Freshly isolated quiescent human HSCs were cultured for two weeks as part of the purification protocol
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and to become fully activated HSCs (h-aHSCs). h-aHSCs were passaged by trypsinization and passages
two to five were used for experiments.
LX-2 cells were obtained from Merk Millipore (SCC064) and used in passages 22–30. Dulbecco’s
modified Eagle’s medium (DMEM) with high glucose supplemented with 10% fecal calf serum and
1% antibiotics was used for culturing them. Cells were passed by trypsinization and medium was
refreshed every 3 days or when necessary. Cells were grown in 5% CO2 and 37 ◦C in ambient air.
2.3. Real-Time Monitoring of Cell Proliferation
Proliferation was assessed using the xCELLigence Real Time Cell Analyzing (RCTA) system
(RTCA DP; ACEA Biosciences, Inc., San Diego, CA, USA). Primary human or rat aHSCs were plated in
E-plates to record cell proliferation, according to the manufacturer’s instructions [12]. Treatment was
started 24 h after attachment and finished after an additional 72 h of treatment. Results were recorded
and analyzed by RTCA software.
2.4. Real-Time Imaging Monitoring of Cell Dynamics
Cell migration, morphology and proliferation were assessed by the Live-Cell Analysis System
Incucyte (Sartorius, Biopharma, Göttingen, Germany). Primary human or rat activated HSCs were
seeded and after 24 h of attachment cells were treated and taken to the IncuCyte ZOOM® platform,
which was housed inside a cell incubator at 37 ◦C/7.5% CO2, for 72 h. Nine images per well from three
technical replicates were taken every 2 h using a 10× objective lens and then analyzed using IncuCyte™
Basic Software.
2.5. RNA Isolation, cDNA Synthesis and Real-Time Quantitative PCR
A quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) was performed
as previously described [13]. Briefly, RNA was isolated from cell cultures using TRIzol® reagent
according to the supplier’s instructions (Thermo Fisher Scientific, Breda, The Netherlands). RNA quality
and quantity were determined using a NanoDrop 2000c UV–vis spectrophotometer (Thermo Fisher
Scientific). The cDNA was synthesized from 2.5 µg RNA using random nanomers and M-MLV reverse
transcriptase (Invitrogen, Carlsbad CA, USA). Taqman primers and probes were designed using
Primer Express 3.0.1 and are shown in Supplementary Table S1. All target genes were amplified
using the Q-PCR core kit master mix (Eurogentec, Liège, Belgium) on a 7900HT Fast Q-PCR system
(Thermo Fisher Scientific). SDSV2.4.1 (Thermo Fisher Scientific) software was used to analyze the data.
Expression of genes is presented in 2-delta CT and normalized to 18S.
2.6. Protein Isolation, Quantification and Western Blot Analysis
Protein samples were prepared for Western blot analysis as described previously [14]. Protein
concentrations were quantified using the Bio-Rad protein assay (Bio-Rad, Hercules, CA, USA) with
bovine serum albumin (BSA) as a standard. Thirty micrograms of protein were separated on
Mini-PROTEAN® TGX™ precast 4–15% gradient gels (Bio-Rad) and transferred to nitrocellulose
membranes using the Trans-Blot Turbo transfer system, (Bio-Rad). Primary antibody details
and dilutions are listed in Supplementary Table S2 and appropriate horseradish peroxidase
(HRP)-conjugated secondary antibodies (1:2000; P0448, DAKO) were used for detection. Proteins were
detected using the Pierce ECL Western blotting kit (Thermo Fisher Scientific). Images were captured
using the ChemiDoc XRS system and Image Lab version 3.0 (Bio-Rad).
2.7. Quantification of Glycolysis and OXPHOS
Extracellular acidification rates (ECARs) and oxygen consumption rates (OCRs) were measured
using glycolysis stress kits and mito stress kits, respectively, in the extracellular flux analyzer Seahorse
(Agilent Technologies, Santa Clara, CA, USA) following the manufacturer’s instructions and as described
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previously (14). Briefly, respiratory chain inhibitors (Oligo: oligomycin, a complex V inhibitor, FCCP:
carbonyl cyanide-p-trifluoromethox- yphenyl-hydrazon, a protonophore and lastly A+R: antimycin A
and rotenone, inhibitors of complex III and I) and glycolysis stimulators/inhibitors (glucose, to stimulate
glycolysis, oligomycin, to inhibit mitochondrial metabolism and help reach glycolysis to its maximum,
and 2-Deoxyglucose, glycolysis inhibitor) were added sequentially as described previously [15] and
following manufacturer’s instructions. OCR and ECAR were measured at 37 ◦C.
2.8. Enzyme Activity and Capacity (Vmax)
Enzymatic activity assays were performed in cellular extracts and all parameters were
adapted from yeast to mammalian cells, as previously described [16]. Briefly, all enzyme activities
were measured in freshly prepared extracts at 37 ◦C in a Synergy H4 plate reader (BioTek,
Winooski, VT, USA) as described previously [17]. For all assays, the reaction mixtures without
start reagent were pre-warmed at 37 ◦C. The conditions used for each enzymatic reaction are
described here: Hexokinase (HK; EC2.7.1.1)—1.2 mmol/L NADP+, 10 mmol/L glucose, 1.8 U/mL
glucose-6-phosphate dehydrogenase (EC1.1.1.49), and 10 mmol/L ATP as start reagent. Phosphoglucose
isomerase (GPI; EC5.3.1.9)—0.4 mmol/L NADP+, 1.8 U/mL glucose-6-phosphate dehydrogenase
(EC1.1.1.49), and 2 mmol/L fructose 6-phosphate as start reagent. Phosphofructokinase (PFK;
EC2.7.1.11)—0.15 mmol/L NADH, 1 mmol/L ATP, 0.5 U/mL aldolase (EC4.1.2.13), 0.6 U/mL
glycerol-3P-dehydrogenase (EC1.1.1.8), 1.8 U/mL triosephosphate isomerase (EC5.3.1.1), and 10 mmol/L
fructose 6-phosphate as start reagent. Aldolase (ALD; EC4.1.2.13)—0.15 mmol/L NADH, 0.6 U/mL
glycerol-3P-dehydrogenase (EC1.1.1.8), 1.8 U/mL triosephosphate isomerase (EC5.3.1.1), and 2 mmol/L
fructose 1,6-bisphosphate as start reagent. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH;
EC1.2.1.12)—0.15 mmol/L NADH, 1 mmol/L ATP, 24 U/mL 3-phosphoglycerate kinase (EC2.7.2.3),
and 5 mmol/L 3-phosphoglyceric acid as start reagent. 3-Phosphoglycerate kinase (PGK;
EC2.7.2.3)—0.15 mmol/L NADH, 1 mmol/L ATP, 8 U/mL glyceraldehyde-3-phosphate dehydrogenase
(EC1.2.1.12), and 5 mmol/L 3-phosphoglyceric acid as start reagent. Phosphoglycerate mutase
(PGAM; EC5.4.2.1)—0.15 mmol/L NADH, 1 mmol/L ADP, 2.5 mmol/L 2,3-diphospho-glyceric
acid, 5 U/mL enolase (EC4.2.1.11), 50 U/mL pyruvate kinase (EC2.7.1.40), 60 U/mL L-lactate
dehydrogenase (EC1.1.1.27), and 5 mmol/L 3-phosphoglyceric acid as start reagent. Enolase
(ENO; EC4.2.1.11)—0.15 mmol/L NADH, 1 mmol/L ADP, 50 U/mL pyruvate kinase (EC2.7.1.40),
15 U/mL L-lactate dehydrogenase (EC1.1.1.27), and 1 mmol/L 2-phosphoglyceric acid as start reagent.
Pyruvate kinase (PK)—0.15 mmol/L NADH, 1 mmol/L ADP, 1 mmol/L fructose 1,6-bisphosphate,
60 U/mL L-lactate dehydrogenase (EC1.1.1.27) and 2 mmol/L phosphoenolpyruvate as start reagent.
Lactate dehydrogenase (LDH)—0.15 mmol/L NADH, and 1 mmol/L pyruvate as start reagent.
Glucose-6-phosphate dehydrogenase (G6PDH)—0.4 mmol/L NADP+, and 5 mmol/L glucose
6-phosphate as start reagent.
2.9. ATP Assay
Primary rat HSCs were seeded in black 96-well plates and after 24 h of attachment, cells were
treated. After 72 h, cells were lysed according to the manufacturer’s instructions (Cell-Triter GLO,
Promega, Madison, WI, USA) and luminescence was recorded in a Synergy H4 (BioTek) plate reader
at RT.
2.10. Immunofluorescence Microscopy
Primary rat HSCs were seeded directly after isolation in 12-well plates containing 18 mm glass
coverslips. Cells on coverslips were washed, fixed (4% PFA, 10 min) and permeabilized (0.1% Triton
X-100, 10 min) prior non-specific blocking (2% BSA, 30 min). After blocking, cell on coverslips were
incubated for 1 h at RT with the primary antibodies goat polyclonal collagen-I (Southern Biotech, 1310-01,
1/200) and mouse monoclonal αSMA (Sigma Aldrich (Munich, Germany), A5228, 1/100), washed three
times with blocking solution and incubated with secondary antibodies goat anti-rabbit Alexa Fluor
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488 or rabbit anti-mouse Alexa Fluor 488 (Thermo Fisher Scientific, 30 min, at RT). After secondary
antibody incubation, coverslips were washed three times and mounted with Vectashield Antifade
Mounting Medium with DAPI (Vector Laboratories, Gdynia, Poland). Coverslips were air-dried, sealed
using nail polish, stored at 4 ◦C and covered from light until further use. Images were obtained in a
Zeiss 410 inverted laser scan microscope (Leica Microsystems, Wetzlar, Germany) with 16× or 40×
magnification objectives using immersion oil and processed using ImageJ software (public domain,
developed at the National Institutes of Health).
2.11. Statistical Analysis
All data are presented as mean ± standard deviation. Significance of differences between groups
was tested by one-way ANOVA and t-tests. Calculations were made using the software GraphPad
Prism 5. Results were considered statistically different with p value < 0.05.
3. Results
3.1. Glycolytic and Mitochondrial Metabolism Are Increased in Activated HSCs
The extracellular acidification rate (ECAR, measure of glycolysis) and oxygen consumption
rate (OCR, measure of mitochondrial OXPHOS) were quantified in quiescent primary rat r-qHSCs
(day 1) and fully activated r-aHSCs (day 7) using a Seahorse extracellular flux analyzer (Figure 1).
Rat qHSCs hardly show any non-glycolytic acidification, while this is readily detectable for r-aHSCs
(Figure 1A, left panel level after 2DG addition; right panel last bar graph). Basal glycolytic activity was
significantly higher (3-fold) in r-aHSCs, when compared to r-qHSCs (Figure 1A, 7.6 ± 2.7 mpH/min/105
cells in r-qHSCs versus 23.4 ± 3.5 mpH/min/105 cells in r-aHSCs; p < 0.0001). Glycolytic capacity
was significantly higher in r-aHSCs compared to r-qHSCs (Figure 1A, 6.2 ± 1.4 mpH/min/105 cells in
r-qHSCs versus 40.5 ± 2.1 mpH/min/105 cells in r-aHSCs; p < 0.01). As a consequence, r-aHSCs showed
a significantly higher reserve glycolytic capacity compared to r-qHSCs (Figure 1A, 8.5 ± 5.2 versus
30.84 ± 4.9 mpH/min/105 cells, respectively; p < 0.01). Basal mitochondrial respiration was even
more pronouncedly enhanced (4.8-fold) in r-aHSCs compared to r-qHSCs (Figure 1C, 305.9 ± 69.0
versus 63.1 ± 4.3 pmol O2/min/105 cells, respectively; p < 0.0001), which was almost completely
attributed to ATP-linked respiration (Figure 1C, 249.2 ± 48.0 versus 27.7 ± 2.5 pmol O2/min/105 cells,
respectively; p < 0.0001). Moreover, r-aHSCs also harbored significantly more spare respiratory capacity,
which culminated in a significantly higher maximum respiration capacity of r-aHSCs compared to
r-qHSCs (Figure 1C, 436.4 ± 92 versus 121.5 ± 15 pmol O2/min/105 cells, respectively; p < 0.0001).
Non-mitochondrial respiration and proton leak, a measure of mitochondrial coupling efficiency [18],
were similar for r-qHSCs and r-aHSCs (Figure 1C).
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to measure glycolytic metabolism; key glycolytic parameters quantified from the data of qHSCs (red) 
and aHSCs (blue); (B) enzymatic activity (Vmax in cell extracts) of key glycolytic enzymes of qHSCs 
(red) and aHSCs (blue); (C) oxygen conspumption rate (OCR) versus time in qHSCs (red) and aHSCs 
(blue) after real-time analysis with a mitochondrial stress kit to measure mitochondrial metabolism; 
key mitochondrial metabolism parameters quantified from the data of qHSCs (red) and aHSCs (blue); 
(D) OCR versus ECAR of qHSCs (red) and aHSCs (blue) to create an energy phenotype plot; n = 3, 
mean ± SEM *p < 0.05, ***p < 0.0001 (one-way ANOVA). 
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and r-aHSCs (3 and 7 days after isolation) was performed. Antibodies against manganese superoxide 
dismutase (MnSOD) were used to visualize mitochondria and rHSC activation was assessed by α-
SMA immunostaining. Figure 2A shows that MnSOD-containing mitochondria are mostly observed 
as individual dots in quiescent HSCs, distributed along the periphery of the cells (Figure 2A, left 
panel), while α-SMA-specific staining was not detected, as expected. Very strong staining of the α-
SMA network was detected in r-aHSCs, cells that had also strongly increased in size (Figure 2A, 
middle panel (day 3) and right panel (day 7)). This was associated with a highly fused MnSOD-
stained mitochondrial network, distributed in close proximity to the nuclei and extended towards 
the cell projections (Figure 2A, middle and right panels) An interconnected mitochondrial phenotype 
thus correlates with a highly energetic state of aHSCs (Figure 1D). Immunostaining of human aHSCs 
with MnSOD and mitofusin 1 (MFN1, as a marker of mitochondrial fusion) revealed that 
mitochondria are highly fused (as seen by the high co-localization of MnSOD and MFN1) and are 
distributed in the perinuclear and extended to the cell extensions (Figure 2B) similar to that seen in 
rat aHSCs. 
Interestingly, LX-2 cells, used as a model of immortalized human HSCs, stained with 
MitoTracker red, showed that mitochondria are also highly fused (Figure 2C). Mitochondrial fusion 
protein MFN1 and MnSOD co-staining in r-qHSCs revealed that these two proteins do not co-localize, 
confirming that MFN1 is not playing a role in mitochondrial fusion in rat qHSCs (Figure 2D). 
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Quantification of the activity of 11 glycolytic enzymes revealed only a significant increase in
phosphoglycerate kinase (PGK, +50%) and glucose-6-phosphate dehydrogenase (G6PDH + 300%)
activity after rHSC activation (Figure 1B). All other enzymes showed similar activities in r-qHSCs
and r-aHSCs, though non-significant increases were noticed for most of them in r-aHSCs. Of note,
the normalization in ECAR analysis was performed per cell number and in glycolytic activity per mg
protein. Taken together, these results suggest a functional upregulation of mitochondrial and glycolytic
metabolism to a highly energetic phenotype (Figure 1D) to support r-aHSC growth, proliferation,
motility and ECM production.
3.2. Mitoch ndrial Fusion Is Increased during Activation of HSCs
Upregulation of mitochondrial metabolism has been linked to mitochondrial fusion in various
cell types [19,20]. To assess mitochondrial fusion, immunofluorescence of freshly isolated r-qHSCs
and r-aHSCs (3 and 7 days after isolation) was performed. Antibodies against manganese superoxide
dismutase (MnSOD) were used to visualize mitochondria and rHSC activation was assessed by α-SMA
immunostaining. Figure 2A shows that MnSOD-containing mitochondria are mostly observed as
individual dots in quiescent HSCs, distributed along the periphery of the cells (Figure 2A, left panel),
while α-SMA-specific staining was not detected, as expected. Very strong staining of the α-SMA
network was detected in r-aHSCs, cells that had also strongly increased in size (Figure 2A, middle
panel (day 3) and right panel (day 7)). This was associated with a highly fused MnSOD-stained
mitochondrial network, distributed in close proximity to the nuclei and extended towards the cell
projections (Figure 2A, middle and right panels) An interconnected mitochondrial phenotype thus
correlates with a highly energetic state of aHSCs (Figure 1D). Immunostaining of human aHSCs with
MnSOD and mitofusin 1 (MFN1, as a marker of mitochondrial fusion) revealed that mitochondria
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are highly fused (as seen by the high co-localization of MnSOD and MFN1) and are distributed in the
perinuclear and extended to the cell extensions (Figure 2B) similar to that seen in rat aHSCs.Cells 2020, 9, x FOR PEER REVIEW 7 of 15 
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experiments. Bar = 50 µm. (B) Immunofluorescence of human aHSCs to assess MnSOD (in red), and 
the mitochondrial fusion protein mitofusin 1 (MFN1, in green), and DAPI (in blue). Bar = 50 µm. (C) 
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Figure 2. Mitochondrial fusion is increased during activation of HSCs. (A) Immunofluorescence of
HSC activation (4 h, 3 d and 7 days after isolation) to assess the mitochondrial enzyme manganese
superosxidase (MnSOD, in green), and the activation marker, alpha-smooth muscle actin (α-SMA)
(in red). Nuclei were stained with DAPI (in blue). Representative pictures from three independent
experiments. Bar = 50 µm. (B) Immunofluorescence of human aHSCs to assess MnSOD (in red),
and the mitochondrial fusion protein mitofusin 1 (MFN1, in green), and DAPI (in blue). Bar = 50 µm.
(C) Im unofluorescence staining of LX-2 cells using MitoTracker (in red) and DAPI (in blue). Bar = 50µm.
(D) Immunofluorescence staining of rat qHSCs to assess mitochondria using MnSOD (in green) and
MFN1 (in red), nuclei were stained with DAPI (in blue). Bar = 10 µm.
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Interestingly, LX-2 cells, used as a model of immortalized human HSCs, stained with MitoTracker
red, showed that mitochondria are also highly fused (Figure 2C). Mitochondrial fusion protein MFN1
and MnSOD co-staining in r-qHSCs revealed that these two proteins do not co-localize, confirming
that MFN1 is not playing a role in mitochondrial fusion in rat qHSCs (Figure 2D).
3.3. Increase in Mitochondrial Fusion during Activation Is Independent of Mitochondrial Biogenesis or
Mitochondrial Copy Number
We next determined whether the increase in mitochondrial metabolism and fusion was due to
increased mitochondrial biogenesis and/or mitochondrial mass. Protein and mRNA levels of the
peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC1-α), a key controller of
mitochondrial biogenesis, were readily detectable in r-qHSCs (day 0 and 1 after isolation; Figure 3A,E).
However, PGC1-α protein levels rapidly dropped upon activation of rHSCs (day 3 and day 7),
concomitant with a reduction in the corresponding Ppargc1a mRNA levels (Figure 3A,E). Interestingly,
protein levels of the voltage-dependent anionic channel (VDAC), located in the outer membrane of
mitochondria, were also strongly downregulated upon rHSC activation (Figure 3A). Activation of
rHSCs was confirmed by a strong induction of α-SMA protein/Acta2 mRNA levels (Figure 3A,E),
in conjunction with increased Col1a1 levels (Figure 3E) and reduced Nr1c3 (encoding PPAR-γ) levels
(Figure 3E). Analysis MFN1 during r-HSC activation showed that it was readily detected in r-qHSCs
(as also observed by immunofluorescence, Figure 2D), and after an early drop in expression during
HSC activation on day 1 and 3, levels rose again in fully activated r-HSCs (Figure 3A). Analysis
of mRNA levels of mitofusin 1 and 2 (Mfn1 and Mfn2) revealed slight upregulation on day 1 after
isolation and a slight decrease on day 7 after isolation (Figure 3E). Analysis of the dynamin-related
protein 1 (DRP1) revealed that only 7 days after isolation, this marker was upregulated at protein
levels (Figure 3A). Interestingly, the corresponding mRNA levels of Dnm1l did not significantly change
during rHSC activation (Figure 3E). The combined mRNA and protein analysis reveals that levels of
factors involved in mitochondrial dynamics appear to be regulated partly in a post-transcriptional
manner during the HSC activation process. Western blot analysis of OXPHOS proteins revealed a
clear decrease in complex III only in day 7 r-aHSCs (Figure 3B), while levels of other components
were rather comparable at the different time points of rHSC activation. Moreover, copy numbers of
mitochondrial DNA (as a proxy for mitochondrial mass) did not change during the rHSC activation
process (Figure 3C). Interestingly, MFN1, DRP1 and phosphorylated DRP1 (p-DRP1) expression was
also readily detected in h-aHSCs as in a-rHSCs, while those proteins were evidently lower in r-qHSCs
(Figure 3E). Taken together, these results show that the increase in mitochondrial metabolism (Figure 1)
and mitochondrial fusion (Figure 2) are independent of mitochondrial biogenesis and/or increase
in mass.
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Figure 3. Increase in mitochondrial fusion during activation is independent of mitochondrial biogenesis
or mitochondrial copy number: (A) Western blots of day 0, day 1, day 3 and day 7 after isolation of HSCs
against PGC1-α (mitochondrial biogenesis), voltage-dependent anionic channel (VDAC) (marker of
mitochondrial mass), MFN1 and dynamin-related protein 1 (DRP1) (markers of mitochondrial fusion),
α-SMA (HSC activation) and Pex-14 (loading control); (B) Western blots of day 0, day 1, day 3 and day 7
after isolation of HSCs to measure the electron transport chain (ETC) complexes; (C) mitochondrial copy
number quantified by relative DNA expression of mitochondrial gene NDH2 to genomic DNA (β-actin)
upon activation of HSCs; (D) Western blots of rat HSCs (day 0 and day 7) and human aHSCs against
MFN1, DRP1, p-DRP1; (E) relative mRNA expression of α-SMA (encoded by acta2), collagen I (encoded
by col1a1), PPARγ (encoded by pparγ), PGC1α (encoded by ppargc1a), MFN1 and MFN1 (encoded by
Mfn1 and MFN2, respectively) and DRP1 (encoded by Dnm1l) versus 18S; n = 3, mean ± SEM * p < 0.05,
*** p < 0.0001 (one-way ANOVA).
3.4. Mitochondrial and Glycolytic Metabolism Are Independently Necessary to Maintain the Activated
State of HSCs
We next made a side-by-side comparison of glycolysis inhibition, glutaminolysis inhibition or
complex I of the mitochondrial electron transport chain (ETC) inhibition in r-aHSCs and h-aHSCs.
We inhibited glycolysis (with 2DG), glutami olysis (with CB-839) or complex I (with rotenone in rat
and metformin in human aHSCs) in r-aHSCs (Figure 4) and h-aHSCs (Figure 5). It is important to note
that none of the treatments led to sig ificant levels of cell death after 72 h (Supplementary Figure S1).
I terestingly, inhibition of glycolysis caused a significant reduction in ACTA2 (encoding α-SMA) and
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COL1A1 (encoding collagen I) mRNA levels only in human aHSCs (Figure 5A) with no effect in r-aHSCs
(Figure 4A). In line with this, inhibiting glycolysis significantly suppressed h-aHSCs proliferation
(Figure 5B; 66.4% ± 8.7 reduction, p < 0.0001), while this was not observed for r-aHSCs (Figure 4C).
Interestingly, 2DG treatment caused a significant reduction in cellular ATP levels in r-aHSCs (Figure 4B).
Similar as observed for glycolysis inhibition, targeting glutaminolysis also had differential effects
in r-aHSCs and h-aHSCs; while ACTA2/Acta2 levels were suppressed by CB-839 treatment in both
r-aHSCs and h-aHSCs, COL1A1 levels were only reduced in h-aHSCs (Figures 4A and 5A). Moreover,
proliferation and cellular ATP levels were not affected by CB-839 in r-aHSCs (Figure 4B,C), while it
significantly reduced h-aHSC proliferation (Figure 5B; 46.9 ± 67.5 reduction, p < 0.001). Importantly,
inhibition of mitochondrial OXPHOS suppressed mRNA levels of ACTA2/Acta2 and COL1A1/Col1a1
in both (rotenone-treated) r-aHSCs and (metformin-treated) h-aHSCs (Figures 4A and 5A), and was
accompanied by impaired cell proliferation (Figures 4C and 5B) and a reduction in cellular ATP
concentrations (Figure 4B) Taken together, these results show that besides glycolysis, mitochondrial
metabolism also supports HSC activation and when inhibited cannot be fully compensated by other
energy-generating pathways.
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4. Discussion
In this study, we show that HSC transdifferentiation is characterized by simultaneous induction of
glycolysis and mitochondrial oxidative phosphorylation (OXPHOS) and is accompanied by extensive
mitochondrial fusion to meet the high energy demands associated with induced cell proliferation,
migration, contraction, migration and ECM production. The HSC transdifferentiation-associated
induction of OXPHOS (~5-fold) was stronger than glycolysis (~3-fold). HSC activation was suppressed
by targeting glycolysis or mitochondrial metabolism, either glutaminolysis or OXPHOS, separately,
but most pronounced by inhibiting OXPHOS. Human activated HSCs appear to be more sensitive
to metabolic inhibitors compared to activated rat HSCs. Thus, metabolic shifts associated with HSC
transdifferentiation reveal novel and potent targets for the treatment of liver fibrosis.
The first question this study sought to determine was the actual contribution of glycolysis
and oxidative phosphorylation towards HSC activation by comparing freshly isolated versus
culture-activated primary HSCs. Several reports have shown that HSCs depend on glycolysis
and glutaminolysis to transdifferentiate towards active HSCs [7,8]. These reports analyzed protein and
mRNA expression of key enzymes in glycolysis and glutaminolysis during rat HSC activation [7,8].
However, actual glycolytic rat and/or mitochondrial respiration were not quantified. Interestingly,
others have shown that plastic-cultured r-aHSCs and LX-2 cells have higher mitochondrial and
glycolytic metabolism compared to matrigel-cultured r-aHSCs and LX-2 cells [9]. Here, we show that
the glycolytic rate is increased approximately 3-fold in culture-activated rHSCs versus freshly isolated
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r-qHSCs. Surprisingly though, the mitochondrial oxygen consumption rate increased even more, by
about 5-fold. This is the first time that the simultaneous activation of glycolysis and mitochondrial
metabolism in culture-activated versus freshly isolated HSCs is reported. Interestingly, the induction
of mitochondrial OXPHOS was accompanied by extensive mitochondrial fusion, without changes
in mitochondrial mass. Mitochondria play a key role in regulating many different processes like
calcium homeostasis, generation and control of reactive oxygen species, regulation of programmed
cell death and ATP production [21]. The mitochondrial morphology is highly linked to its functions.
Mitochondrial fragmentation occurs in response to nutrient excess and cellular dysfunction and
mitochondrial fusion is associated with increased cell bioenergetic demands [19]. This suggests that the
increase in mitochondrial fusion is a direct response to the increasing energetic demand during HSC
activation. Surprisingly, the observed increase in mitochondrial respiration (5-fold) and mitochondrial
fusion was not accompanied by elevated levels of mitochondrial ETC complex proteins. This might
be explained by the fact that the mitochondrial ETC proteins form super complexes in response to
high energy demands [22] to create a more efficient ETC machinery without upregulating total protein
levels. It needs to be noted though that the normalization in the two methods, e.g., mitochondrial
respiration per cell number and ETC proteins per total cellular protein, is different. HSCs grow
enormously in size, and thus protein content, during activation in vitro, and the absolute amount
of mitochondrial ETC protein increase along with it. Still, mitochondrial DNA copy number did
not increase during HSC transdifferentiation. Thus, it will be interesting to analyze whether ETC
super complexes indeed are formed in activating HSCs to accommodate the high energy demands for
cell proliferation, migration, contraction and ECM production. Interestingly, mitochondrial fusion
was also observed in human primary culture-activated HSCs and in LX-2 cells, suggesting it is a
well-conserved process. Unfortunately, we were not able to compare mitochondrial morphology and
activity in isolated human qHSCs versus aHSCs, as the isolation and purification protocol of human
HSCs from resected liver tissue includes a culturing phase where plastic-adherent HSCs are enriched
over other contaminating hepatic cell types (such as hepatocytes and endothelial cells). The human
HSCs rapidly activate in this culturing step, precluding a direct comparison of qHSCs versus aHSCs.
We observed a strong downregulation of PGC1-α and VDAC during the activation of HSCs,
suggesting a decrease in mitochondrial biogenesis and mass. PGC1-α is a co-activator of PPARγ,
which is a transcription factor that is markedly downregulated during HSC activation. However, the
role of PGC1-α in mitochondrial biogenesis is mostly driven by its role as a co-activator of nuclear
respiratory factor 2 (NRF2) [23]. Given the fact that PPARγ is virtually absent in aHSCs, the reduced
levels of PGC1-α may therefore remain sufficient to activate NRF2 and maintain mitochondrial copy
number. The accompanying reduction in VDAC protein levels during HSC activation might be due to
a differential stability and/or turnover of this protein compared to total mitochondrial turnover.
To unravel new metabolic targets to treat liver fibrosis, we inhibited glycolysis (by 2DG), as well as
two mitochondrial metabolic pathways, i.e., glutaminolysis (by CB-839) and OXPHOS (by rotenone and
metformin). Inhibiting glycolysis suppressed cell proliferation and expression of fibrogenic markers in
fully activated human HSCs. Surprisingly, though, this was not observed for fully activated rat HSCs.
The latter result seems to contradict an earlier report [7] that observed significant anti-proliferative and
anti-fibrogenic effects of 2DG in rat HSCs [7]. In that study, 2DG treatments were started 3 days after rat
primary HSC isolation followed by an exposure to 2DG for an additional 3 days. Three day-cultured
rat HSCs are, however, not fully activated yet. In contrast, we started 2DG treatment 7 days after
isolation, a stage where maximum activation is achieved and reversal, rather that prevention, of the cell
proliferation and fibrogenic phenotype of HSCs can be established. This may suggest that inhibiting
glycolysis during the activation indeed suppresses fibrogenesis, but once full HSC activation is reached,
2DG is not really effective in reversing the fibrogenic phenotype of rat HSCs. Interestingly, 2DG
treatment in r-aHSCs decreased cellular ATP levels, however, this was not sufficient to suppress
cell proliferation and activation markers in r-aHSCs. Still, 2DG did suppress cell proliferation and
expression of fibrogenic markers in fully activated human HSCs which indicates that this may be
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species dependent. Unfortunately, inhibitors of glycolysis that have potent “therapeutic” effects in
in vitro experiments studying cancer cell proliferation have not yet been successfully implemented for
the treatment of patients [24]. 2DG itself reached phase I/II clinical trials for anti-cancer treatment after
encouraging animal experiments, but was discontinued for phase 3 clinical trials because no significant
effects on tumor growth was observed in patients (https://clinicaltrials.gov/ct2/show/NCT00633087).
Furthermore, it has been recently described that targeting hexokinase 2, one of the rate-limiting
enzymes in glycolysis, with the natural compound costunolide, was highly efficient in reducing HSC
activation in vitro and preventing liver damage in vivo [25,26]. This suggests that inhibiting glycolysis,
with better compounds, could be a potential strategy to treat liver fibrosis.
Mitochondrial metabolism is upregulated 5-fold in aHSCs versus qHSCs, so we targeted
mitochondrial metabolism by inhibiting glutaminase with CB-839, complex I of the ETC with metformin
(in human HSCs) and rotenone (in rat HSCs). CB-839 is a novel glutaminase inhibitor that is currently
being evaluated in several clinical trials to test its anti-carcinogenic properties in patients, as it effectively
kills cancer cells in in vitro and in vivo models [27–29]. Similar as observed for 2DG, CB-839 had
different effects in fully activated human and rat HSCs; it significantly suppressed proliferation
and expression of fibrogenic markers in human HSCs, while minimal to no effects were observed
for rat HSCs. The results using human HSCs are promising, though, and may further support the
notion that human HSCs rely more on different energy-generating metabolic processes than rat HSCs.
CB-839 was developed to specifically inhibit the glutaminase C (GAC) splice variant of the human
glutaminase (GLS1) gene [28], so species differences of this specific splicing variant could also affect
the pharmacodynamics of this drug. Interestingly, it has been shown that culturing primary human
and rat HSCs in media lacking glutamine in the presence of glucose significantly delays proliferation
and activation [8]. The expression of glutaminase is enhanced in chronically injured human livers,
providing further support that targeting glutaminolysis with glutaminase inhibitors (such as BPAN
and CB-839) may become a successful approach for treating liver fibrosis.
The most important and novel finding of our work was that targeting complex I of the mitochondrial
ETC with either metformin (in human HSCs) or rotenone (in rat HSCs) most potently suppressed the
proliferation and expression of fibrogenic markers in HSCs. Furthermore, rotenone reduced cellular
ATP levels in r-aHSCs, suggesting these cells rely on mitochondrial-derived ATP to proliferate and
maintain the activated status. This uncovers mitochondrial OXPHOS as a novel therapeutic target for
the treatment of liver fibrosis. Metformin has been in clinical use for the treatment of metabolic disease,
particularly type 2 diabetes, for decades already. Interestingly, metformin reduced the mortality rate
by 57% in diabetic patients with cirrhotic liver disease [30]. Though this does not provide proof that
this is related to an anti-fibrotic effect of metformin, other studies also support this therapeutic action
of metformin. For instance, metformin suppressed COL1A1 expression and induced lipogenic genes in
human lung fibroblasts in vitro [31]. Moreover, it reversed already established lung fibrosis in mice [32].
Thus, metformin, and inhibitors of mitochondrial OXPHOS in general, may have therapeutic potential
in the treatment of liver fibrosis in chronic liver diseases.
In summary, we show that HSC activation is associated with simultaneous induction of glycolysis
and mitochondrial metabolism to support the high energy demand associated with a fibrogenic
phenotype. This uncovers novel targets for developing effective therapies to halt and/or reverse liver
fibrosis, specifically targeting mitochondrial glutaminolysis or inhibiting the complex I of the ETC.
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Figure S1: Toxicity of inhibitors used in primary human HSCs and primary rat HSCs; Table S1: List of primers and
probes used. Gene, probe sequence, forward and reverse primer sequence, and species listed for each of the genes
used; Table S2: List of antibodies used. Protein, type of antibody, company and catalog number and dilutions
used for western-blot and immunofluorescence of each of the antibodies used.
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